China Preliminarily Sets Principles For The Next Round Drug Price Cuts
This article was originally published in PharmAsia News
Sources disclosed that China’s next round of mandatory drug price reductions will mainly affect cancer, cardiovascular, and infectious disease therapies and will lower the prices of general medicines by 15% on average, off-patent drugs by 10%, and patented drugs by 7%.
You may also be interested in...
Industry associations in the US and Canada have welcomed revisions to the proposed US-Mexico-Canada trade agreement that remove potentially damaging provisions around biologic data exclusivity and include measures favorable to generics, including incentives for generic competition.
NeuClone has reported that its NeuCeptin proposed biosimilar trastuzumab has successfully met all primary and secondary endpoints in a Phase I clinical trial.
Products from Novartis, Celgene and Merck could get an EU approval recommendation at this week's CHMP meeting.